Form 4 for INSM INSMED Inc
Accepted 2025-09-04 00:00:00 ET · period of report 2025-09-02 · accession 0001796960-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-09-04 | 2025-09-02 | INSM | Flammer Martina M.D. | Chief Medical Off | S - Sale+OE | $144.34 | -186.6K | 181.5K | -51% | -$26.94M |
| DM | 2025-09-04 | 2025-09-02 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $23.40 | +186.6K | 269.8K | +225% | +$4.37M |
| DM | 2025-09-04 | 2025-09-02 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $0.00 | -186.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-02 | S | D | 63,782 | $145.33 | 117,726 | D | — | — | (F6) This is the weighted average sales price representing 63,782 shares sold at prices ranging from $144.70 to $145.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 2 | Common | Common Stock | 2025-09-02 | S | D | 34,615 | $146.05 | 83,111 | D | — | — | (F7) This is the weighted average sales price representing 34,615 shares sold at prices ranging from $145.70 to $146.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 3 | Common | Common Stock | 2025-09-02 | S | D | 35,245 | $143.16 | 209,571 | D | — | — | (F4) This is the weighted average sales price representing 35,245 shares sold at prices ranging from $142.70 to $143.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2025-09-02 | M | A | 13,680 | $34.03 | 96,791 | D | — | — | |
| 5 | Common | Common Stock | 2025-09-02 | M | A | 17,160 | $26.46 | 113,951 | D | — | — | |
| 6 | Common | Common Stock | 2025-09-02 | M | A | 25,710 | $26.43 | 139,661 | D | — | — | |
| 7 | Common | Common Stock | 2025-09-02 | M | A | 38,846 | $17.07 | 178,507 | D | — | — | |
| 8 | Common | Common Stock | 2025-09-02 | M | A | 13,072 | $19.74 | 191,579 | D | — | — | |
| 9 | Common | Common Stock | 2025-09-02 | M | A | 36,555 | $18.95 | 228,134 | D | — | — | |
| 10 | Common | Common Stock | 2025-09-02 | M | A | 23,835 | $29.13 | 251,969 | D | — | — | |
| 11 | Common | Common Stock | 2025-09-02 | M | A | 17,790 | $25.83 | 269,759 | D | — | — | |
| 12 | Common | Common Stock | 2025-09-02 | S | D | 19,066 | $141.27 | 250,693 | D | — | — | (F2) This is the weighted average sales price representing 19,066 shares sold at prices ranging from $140.56 to $141.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 13 | Common | Common Stock | 2025-09-02 | S | D | 5,877 | $142.03 | 244,816 | D | — | — | (F3) This is the weighted average sales price representing 5,877 shares sold at prices ranging from $141.61 to $142.55 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 14 | Common | Common Stock | 2025-09-02 | S | D | 28,063 | $144.05 | 181,508 | D | — | — | (F5) This is the weighted average sales price representing 28,063 shares sold at prices ranging from $143.70 to $144.63 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 15 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 17,160 | $0.00 | 0 | D | $26.46 · — to 2031-05-12 | 17,160 Common Stock | (F8) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 16 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 25,710 | $0.00 | 8,570 | D | $26.43 · — to 2032-01-06 | 25,710 Common Stock | (F9) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 17 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 38,846 | $0.00 | 25,898 | D | $17.07 · — to 2032-05-11 | 38,846 Common Stock | (F9) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 18 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 13,072 | $0.00 | 13,073 | D | $19.74 · — to 2033-01-05 | 13,072 Common Stock | (F9) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 19 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 36,555 | $0.00 | 73,110 | D | $18.95 · — to 2033-05-11 | 36,555 Common Stock | (F9) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 20 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 17,790 | $0.00 | 53,370 | D | $25.83 · — to 2034-05-13 | 17,790 Common Stock | (F10) The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the Initial Vesting Date. |
| 21 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 23,835 | $0.00 | 39,725 | D | $29.13 · — to 2034-01-04 | 23,835 Common Stock | (F9) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 22 | Derivative | Stock Option (right to buy) | 2025-09-02 | M | D | 13,680 | $0.00 | 0 | D | $34.03 · — to 2031-01-07 | 13,680 Common Stock | (F8) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |